Pancreatitis - chronic
Methodology & AI Transparency ⓘ
Pancreatitis - chronic Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Pancreatitis - chronic—coded clinically as K86.1 across Liver & Hepatology guidelines—combines hepatotoxic medication audit [Pancreatitis - chronic K86.1] with structured follow-up of ALT, AST, Alkaline in Pancreatitis - chronic (K86.1: Phosphatase & GGT) (ALT < 25 U/L (men) / < 19 U/L (women) (K86.1)).
- 2 Real-world patient consensus: Clinical coding for Pancreatitis - chronic uses ICD-10 K86.1 across Liver & Hepatology specialty care.
- 3 Typical cash cost range: Differential triage of Pancreatitis - chronic (K86.1) utilizes hepatotoxic medication audit [Pancreatitis - chronic K86.1].
- 4 Top reported side effects / signs: Key Liver & Hepatology biomarkers for Pancreatitis - chronic (K86.1): Fasting Lipase & in Pancreatitis - chronic (K86.1: Triglycerides) & ALT, AST, Alkaline in Pancreatitis - chronic (K86.1: Phosphatase & GGT) (ALT < 25 U/L (men) / < 19 U/L (women) (K86.1)).
Ask our AI Specialists anything about Pancreatitis - chronic
What Is Pancreatitis - chronic?
Pancreatitis - chronic—coded clinically as K86.1 across Liver & Hepatology guidelines—combines hepatotoxic medication audit [Pancreatitis - chronic K86.1] with structured follow-up of ALT, AST, Alkaline in Pancreatitis - chronic (K86.1: Phosphatase & GGT) (ALT < 25 U/L (men) / < 19 U/L (women) (K86.1)).
Pathophysiology, Underlying Causes & Clinical Presentation
Pancreatitis - chronic (K86.1) alters liver & hepatology homeostasis through cholestatic bile-duct obstruction [Pancreatitis - chronic K86.1]; clinical remission targets ALT, AST, Alkaline in Pancreatitis - chronic (K86.1: Phosphatase & GGT) within ALT < 25 U/L (men) / < 19 U/L (women) (K86.1).
Common Symptoms & Clinical Signs
- • Presentation of Pancreatitis - chronic (K86.1): epigastric pain, steatorrhea [Pancreatitis - chronic K86.1]
- • Secondary Pancreatitis - chronic clinical sign: asymptomatic elevation of in Pancreatitis - chronic (K86.1: liver transaminases)
- • Symptom flares in Pancreatitis - chronic correlating with Fasting Lipase & in Pancreatitis - chronic (K86.1: Triglycerides) deviation outside Normal enzymatic baseline (K86.1)
- • Functional liver & hepatology impact requiring hepatotoxic medication audit [Pancreatitis - chronic K86.1] evaluation (K86.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Pancreatitis - chronic Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K86.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Liver, Gallbladder & Pancreatic Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipase & in Pancreatitis - chronic (K86.1: Triglycerides) | Normal enzymatic baseline (K86.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT, AST, Alkaline in Pancreatitis - chronic (K86.1: Phosphatase & GGT) | ALT < 25 U/L (men) / < 19 U/L (women) (K86.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: FIB-4 Hepatic Fibrosis in Pancreatitis - chronic (K86.1: Index) | < 1.30 (K86.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pancreatitis - chronic
Treatment selection for Pancreatitis - chronic depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pancreatitis - chronic)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Glucagon-like peptide-1 receptor agonists and: What a 14,972-Participant Study Found The present meta-analysis does not suggest any increase in the risk of pancreatitis with the use of GLP-1RA. Diabetes research and clinical practice • 2014-02-15 • Meta-Analysis | N = 14,972 | 99/100 | PMID 24485345 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Plozasiran significantly lowered circulating TG levels, with substantial reduction in recurrent AP for participants with very severe hypertriglyceridemia and history of AP. Alimentary pharmacology & therapeutics • 2026-05-15 • Phase III Randomized Trial | N = 67 | 88/100 | PMID 41923352 ↗ |
| What the Latest Evidence Really Says About Serious side effects reported with exenatide and liraglutide: acute pancreatitis Current available published evidence is insufficient to support an increased risk of AP or cancer associated with GLP-1 agonists. Diabetes research and clinical practice • 2012-11-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 23010561 ↗ |
| Can This Approach Help? Inside the Latest Research on Low-molecular-weight heparin in the treatment of moderately severe and severe Use of low-molecular-weight heparin in early stage of moderately severe and severe acute pancreatitis significantly reduces the chance of disease progression and pancreatic necrosis. International journal of surgery (London, England) • 2022-05-15 • Phase III Randomized Trial | N = 140 | 82/100 | PMID 35489648 ↗ |
| Can This Approach Help? Inside the Latest Research on Trial comparing effects of weight loss by liraglutide with lifestyle modification Liraglutide was effective for decreasing weight, liver steatosis and hepatocellular apoptosis in obese adults with NAFLD, but benefits were not sustained after discontinuation, in. Liver international : official journal of the International Association for the Study of the Liver • 2019-05-15 • Randomized Controlled Trial | N = 15 | 82/100 | PMID 30721572 ↗ |
Pancreatitis - chronic Patient Community & “People Like Me” Threads
Filter Pancreatitis - chronic community threads and patient logs by age, biological sex, dosage, and treatment duration.